RESUMO
BACKGROUND: We evaluated whether multidisciplinary disease management programme developed with collaboration of physicians and nurses inside and outside general district hospital settings can affect clinical outcomes in heart failure population over a 12-month period. METHODS: 571 patients hospitalised with CHF were referred to our unit and 509 patients agreed to participation. The intervention team included physicians and nurses from Internal Medicine and Cardiac Dept., and the patient's general practitioners. Contacts were on a pre-specified schedule, included a computerised programme of hospital visits and phone calls; in case of NYHA functional class III and IV patients, home visits were also planned. RESULTS: The median age of patients was 77.7+/-9 years (43.3% women). At baseline the percentage of patients with NYHA class III and IV was 56.0% vs. 26.0% after 12 months (P<0.05). Programme enrolment reduced total hospital admissions (82 vs. 190, -56%, P<0.05), number of patients hospitalised (62 vs. 146, 57%, P<0.05). All NYHA functional class benefited (class I=75%, class IV=67%), with reduction in the costing (-48%, P<0.05). Improvement in symptoms (-9.0+/-3.2) and signs (-5.2+/-3.1) scores was measured (P<0.01). Therapy optimisation was obtained by 20.5% increase in patients taking betablockade and 21.0% increase in those on anti-aldosterone drugs. CONCLUSIONS: Multidisciplinary approach to CHF management can improve clinical management, reducing hospitalisation rate and costing.
Assuntos
Gerenciamento Clínico , Insuficiência Cardíaca/terapia , Avaliação de Processos e Resultados em Cuidados de Saúde , Equipe de Assistência ao Paciente , Idoso , Aconselhamento , Feminino , Insuficiência Cardíaca/economia , Hospitalização/economia , Hospitais de Distrito/economia , Humanos , Itália , Masculino , Equipe de Assistência ao Paciente/economia , Educação de Pacientes como Assunto , Estudos ProspectivosRESUMO
Defibrillation as soon as possible is the mainstay of modern emergency system in the treatment of sudden cardiac death. The emergency medical system (EMS) should be integrated with first responders in the community trained to use the semiautomatic external defibrillators (AED). Piacenza Progetto Vita is a European project of early defibrillation through lay first responders integrated within the EMS. After 22 months of the project 1 285 first responders were trained to the use of AED. Survival from sudden cardiac arrest significantly increased (from 3.3% to 10.5%, p<0.01). In particular in the group of patients treated by first responders survival from ventricular fibrillation was 44.1% vs 21.2% of EMS treated group (p < 0.05). A simple training for the use of AED without cardiopulmonary resuscitation training increased survival and created a group of competent AED operator integrated within the EMS.
Assuntos
Morte Súbita Cardíaca/prevenção & controle , Cardioversão Elétrica , Idoso , Cardioversão Elétrica/economia , Cardioversão Elétrica/instrumentação , Serviços Médicos de Emergência , Humanos , Itália , Análise de SobrevidaAssuntos
Arritmias Cardíacas/terapia , Desfibriladores Implantáveis , Cardioversão Elétrica , Hospitalização/estatística & dados numéricos , Readmissão do Paciente/estatística & dados numéricos , Arritmias Cardíacas/mortalidade , Custos e Análise de Custo , Falha de Equipamento/economia , Hospitalização/economia , Humanos , Readmissão do Paciente/economiaRESUMO
The proliferative activity of the haematopoietic and plasma cells in bone marrow was evaluated under normal and neoplastic conditions, by means of a sequential double immunostaining technique, using monoclonal antibody MIB-1 recognizing the cell proliferation-associated nuclear antigen Ki-67, and antibodies against glycophorin-C, myeloperoxidase, factor VIII-related antigen, and immunoglobulin light chains. Fifty-eight B5 fixed, paraffin-embedded bone marrow biopsies were analysed, including 11 normal controls. 10 cases of myelodysplasia, 14 cases of chronic myeloproliferative disorder, eight cases of acute non-lymphoid leukaemia, and 15 cases of myeloma. In normal marrows, the highest proliferative activity was noticed in the erythroid cells (75% to 95%; mean 90%), in comparison with myeloid precursors (15% to 80%; mean 38%), and megakaryocytes (10% to 20%; mean 14%): no Ki-67 positive plasma cells were found. In all investigated haematological disorders, the expression of MIB-1 by erythroid cells was similar to that observed in controls. Similarly, the percentage of MIB-1 + myeloid precursors in chronic myeloproliferative disorders and myelodysplasia largely overlapped the values observed in normals, and comparable values were also found in the blast cells from acute non-lymphoid leukaemia type M1 and M2. These findings suggest that the evaluation of either erythroid or myeloid proliferative activity is of little value in the differential diagnosis between these myeloproliferative disorders. By contrast, the obvious increase of Ki-67 expression of megakaryocytes in chronic myeloproliferative disorders, with labelling also of micro-megakaryocytes, might sustain the diagnosis in controversial cases. Since cases of mature myeloma showed less than 2% of Ki-67 positive cells, evaluation of proliferative activity is of no value in the differential diagnosis with reactive plasmacytosis. The sequential double immunophenotyping for Ki-67 antigen and for haematopoietic cell lineage-associated markers can be applied in a consistent manner to routine bone marrow biopsies to evaluate proliferating cells in normal and neoplastic conditions.